Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · TORNTPHARM

TORRENT PHAR

HealthcarePharmaceuticals & Biotechnology₹176413 cr market cap
₹4611.00 ▲ +0.01% today As of 19 Nov 2026
52-week low ₹3686.5052-week high ₹5122.80

-10.0% from the 52-week high · +25.1% above the low

Torrent Pharmaceuticals Ltd. engages in the research, development, manufacture, and marketing of generic pharmaceutical formulations. The company is headquartered in Ahmedabad, Gujarat and currently employs 13,573 full-time employees. The firm is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain, gynecology, and dermatology. The firm is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its acne/facecare products brands include Clinmiskin, ACNEMOIST, TRACNILO and fash. The firm's hair/scalp care products brands include Proanagen, Perlice, Permite and NOSKURF. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim. The firm's primary channel of distribution is through the wholesale drug distributors, stockiest and retail pharmacies.

The short version. TORRENT PHAR reported revenue of ₹4,979 crore for Sep 2026, up 50.8% from a year earlier. Net profit was ₹534 crore (down 9.6% year on year). Return on equity was 25.8% in Mar 2026. Promoter holding was 60.78% in Sep 2026, down 7.53 points over 8 quarters.

1 · The price

How has the stock traded?

TORRENT PHAR trades 10.0% below its 52-week high and 25.1% above its 52-week low.

Change over period: —

1M+1.1%
3M-8.0%
6M+4.1%
1Y+21.6%

2 · The business

Is it growing?

Sales, year on year+50.8%

Sep 2026 revenue of ₹4,979 cr.

Profit, year on year-9.6%

Sep 2026 net profit of ₹534 cr.

Net margin10.7%

7.2 pts lower than a year earlier.

3-year growth20.2% profit

Revenue compounded at 12.8% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue49794921419733033302317829592809
Net profit534566389635591548498503
Net margin %10.711.59.319.217.917.216.817.9
EPS (₹)14.0416.7211.4918.7617.4616.1914.7114.86

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue13980115161072896208508800579397673
Net profit216319111656124577712521025436
Net margin %15.516.615.412.99.115.612.95.7
EPS (₹)63.9156.4648.9336.7922.9636.9930.2912.88

3 · The quality

How well does it turn capital into profit?

Return on equity was 25.8% in Mar 2026; debt to equity is 1.76.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %25.825.224.120.1
Return on capital %9.128.528.122.8
EBITDA margin %31.532.232.629.9
Net margin %15.616.615.312.9

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR12.8%11.5%
Profit CAGR20.2%11.6%
Debt to equity1.76
Interest cover8.5x
Current ratio1.13
P/E ratio78.1

4 · The owners

Who holds it, and are they adding?

Promoter holding60.78%

Down 7.53 pts over 8 quarters.

Foreign institutions17.22%

Up 1.05 pts over 8 quarters.

Domestic institutions13.46%

Up 5.11 pts over 8 quarters.

Mutual fund schemes390

+90 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter68.3168.3168.3168.3168.3168.3168.3160.78-7.53
FII16.1716.3116.0915.9216.1316.1815.4417.22+1.05
DII8.358.358.659.289.149.069.8313.46+5.11
Public7.177.036.946.496.426.456.428.54+1.37

Mutual fund holdings · Oct 2026

390 schemes hold this stock

300 the month before.

  • ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND8.83% of NAV
  • quant Healthcare Fund8.46% of NAV
  • PGIM INDIA HEALTHCARE FUND8.34% of NAV
  • Baroda BNP Paribas Health and Wellness Fund7.74% of NAV
  • ICICI Prudential Nifty Pharma ETF6.71% of NAV
  • Nippon India Nifty Pharma ETF6.71% of NAV
  • ICICI Prudential Nifty Pharma Index Fund6.71% of NAV
  • Mirae Asset Healthcare Fund6.41% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for TORRENT PHAR are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about TORRENT PHAR

What is the TORRENT PHAR share price?

TORRENT PHAR (TORNTPHARM) last closed at ₹4,611.00, up 0.01% on the day. Its 52-week range is ₹3,686.50 to ₹5,122.80.

What is the market cap of TORRENT PHAR?

TORRENT PHAR has a market capitalisation of about ₹176,413 crore. Its price-to-earnings ratio is 78.1.

How are TORRENT PHAR's latest results?

TORRENT PHAR reported revenue of ₹4,979 crore for Sep 2026, up 50.8% from a year earlier. Net profit was ₹534 crore (down 9.6% year on year). Return on equity was 25.8% in Mar 2026. Promoter holding was 60.78% in Sep 2026, down 7.53 points over 8 quarters.

Who owns TORRENT PHAR?

As of Sep 2026, shareholding was: Promoter 60.78%, FII 17.22%, DII 13.46%, Public 8.54%.

How many mutual funds hold TORRENT PHAR?

390 mutual fund schemes held TORRENT PHAR in October 2026. That compares with 300 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 29 May 2026 · Final Dividend - Rs. 9
  • 18 Feb 2026 · Interim Dividend - Rs. 29
  • 20 Jun 2025 · Final Dividend - Rs. 6
  • 31 Jan 2025 · Interim Dividend - Rs. 26
  • 21 Jun 2024 · Final Dividend - Rs. 6
  • 12 Feb 2024 · Interim Dividend - Rs. 22

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.